Treatment of pathological stage T3N+M0 bladder cancer: the case for observation.
Corral
D A
DA
Division of Urologic Surgery, University of Pittsburgh, Medical Center, Pittsburgh Cancer Institute, PA 15213.
Bahnson
R R
RR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005708:Gallium / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D009944:Organoplatinum Compounds; C055423:didimethylsulfoxide dichloroplatinum(II); D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D005708:Gallium; D002945:Cisplatin; C027235:gallium nitrate; D008727:Methotrexate